Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28609789 | 0.88 | MEN1 (0.34) | ALDH1A1TSHRMEN1KMT2AMCL1 | |
| SCHEMBL13063974 | 0.83 | ALDH1A1 (0.34) | ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL28063767 | 0.83 | MEN1 (0.36) | ALDH1A1TSHRMEN1KMT2AMCL1 | |
| SCHEMBL382635 | 0.82 | ALDH1A1 (0.33) | ALDH1A1TSHRMEN1KMT2ADGAT1 | |
| SCHEMBL1963 | 0.80 | ALDH1A1 (0.50) | ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL14997782 | 0.79 | MEN1 (0.39) | ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL8489394 | 0.78 | DGAT1 (0.39) | ALDH1A1TSHRMEN1KMT2ADGAT1 | |
| SCHEMBL10900919 | 0.77 | CYP2C19 (0.35) | ALDH1A1TSHRPOLB | |
| SCHEMBL16268291 | 0.77 | MEN1 (0.47) | ALDH1A1TSHRMEN1KMT2AMCL1 | |
| SCHEMBL15584136 | 0.77 | MEN1 (0.32) | ALDH1A1TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | ALDH1A1 422/4885TSHR 4347/4885MEN1 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.